Biodesix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDSX research report →
Companywww.biodesix.com
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- CEO
- Scott Hutton
- IPO
- 2020
- Employees
- 273
- HQ
- Boulder, CO, US
Price Chart
Valuation
- Market Cap
- $116.98M
- P/E
- -4.34
- P/S
- 1.22
- P/B
- 15.19
- EV/EBITDA
- -8.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 82.08%
- Op Margin
- -25.91%
- Net Margin
- -33.26%
- ROE
- -2101.40%
- ROIC
- -30.51%
Growth & Income
- Revenue
- $88.50M · 24.08%
- Net Income
- $-35,265,000 · 17.86%
- EPS
- $-4.67 · 29.24%
- Op Income
- $-27,766,000
- FCF YoY
- 54.37%
Performance & Tape
- 52W High
- $20.21
- 52W Low
- $5.00
- 50D MA
- $14.19
- 200D MA
- $10.07
- Beta
- 0.42
- Avg Volume
- 97.82K
Get TickerSpark's AI analysis on BDSX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | PATIENCE JOHN | other | 1,361 |
| Mar 31, 26 | PATIENCE JOHN | other | 1,361 |
| Feb 20, 26 | Pestano Gary Anthony | other | 1,528 |
| Feb 23, 26 | Pestano Gary Anthony | sell | 556 |
| Feb 20, 26 | Pestano Gary Anthony | other | 1,528 |
| Feb 20, 26 | O'Kane Kieran | other | 1,469 |
| Feb 23, 26 | O'Kane Kieran | sell | 535 |
| Feb 20, 26 | O'Kane Kieran | other | 1,469 |
| Feb 20, 26 | Cowie Robin Harper | other | 1,469 |
| Feb 23, 26 | Cowie Robin Harper | sell | 535 |
Our BDSX Coverage
We haven't published any research on BDSX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BDSX Report →